|Bid||0.00 x 23800|
|Ask||0.00 x 625000|
|Day's Range||116.52 - 116.85|
|52 Week Range||104.06 - 118.22|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
German drugmaker Bayer won the U.S. Food and Drug Administration's priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline. Based on results of a Phase II study, the FDA plans to review Bayer's copanlisib within six months instead of the usual 10 for use against follicular lymphoma which has returned or persisted despite at least two prior therapies, the company said in a statement on Wednesday. Bayer, which is taking over U.S. seeds group Monsanto , is trying to follow up in its drug development efforts on the recent success of blood thinner Xarelto and anti-blindness treatment Eylea.
The divestment was part of a divestment required by South Africa's competition committee.
Bayer has agreed to sell its Liberty herbicide and LibertyLink-branded seeds businesses to win antitrust approval for its acquisition of Monsanto, it said on Monday. The divestment of the two global brands, a requirement imposed by South Africa's Competition Commission on Sunday, will account for the bulk of asset sales worth about $2.5 billion which need to be made to satisfy competition regulators looking at the $66 million Monsanto deal, sources close to the matter have said.